Emily Faucette
Investor Relations Kontakt bei TALIS BIOMEDICAL CORPORATION
Profil
Emily Faucette is currently the SVP-Communications & Investor Relations at Talis Biomedical Corp.
Prior to this, she was the Senior VP-Global Corporate Affairs & IR at Portola Pharmaceuticals LLC in 2020.
She also held the position of Vice President-IR & Corporate Communications at Genomic Health, Inc. Ms. Faucette completed her undergraduate degree at American University.
Aktive Positionen von Emily Faucette
| Unternehmen | Position | Beginn |
|---|---|---|
| TALIS BIOMEDICAL CORPORATION | Investor Relations Kontakt | 01.01.2021 |
Ehemalige bekannte Positionen von Emily Faucette
| Unternehmen | Position | Ende |
|---|---|---|
| PORTOLA PHARMACEUTICALS, INC. | Investor Relations Kontakt | 01.07.2020 |
| GENOMIC HEALTH, INC. | Investor Relations Kontakt | - |
Ausbildung von Emily Faucette
| American University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| TALIS BIOMEDICAL CORPORATION | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Genomic Health, Inc.
 Genomic Health, Inc. Medical SpecialtiesHealth Technology Genomic Health, Inc. engages in the provision of genomic-based diagnostic tests. Its tests analyze the underlying biology of cancers, allowing physicians and patients to make individualized treatment decisions. The firm uses a platform which translates a massive amount of clinical and genomic data into clinically actionable results for treatment planning. The company was founded by Patrick F. Terry, Joffre B. Baker, Randal W. Scott, and Steven Shak in August 2000 and is headquartered in Redwood City, CA. | Health Technology |
Portola Pharmaceuticals LLC
 Portola Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Portola Pharmaceuticals, Inc. engaged in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. It offers Andexxa and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA. | Health Technology |
